Компания Inventiva завершила реструктуризацию warrants с Европейским инвестиционным банком

Inventiva S.A. (NASDAQ:IVA) is one of the best strong buy penny stocks to invest in now. Inventiva S.A. (NASDAQ:IVA) announced on July 9 the completion of the final step of the transactions previously announced on June 2, 2026, through the issuance of approximately 15.7 million new warrants to the European Investment Bank, along with the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 that were not repurchased in the Combined Transaction. Andrew Obenshain, CEO of Inventiva S.A. (NASDAQ:IVA), stated that the completion of the EIB warrant restructuring marks a notable step in bolstering the company's capital structure and improving alignment with its shareholders, and added that through the replacement of the remaining legacy EIB warrants with a simplified warrant instrument that no longer includes specific contractual anti-dilution protection mechanisms, the company has managed to eliminate a potential source of future uncertainty and dilution. This provides the company with increased financial flexibility, according to Obenshain, as it continues to advance the development of lanifibranor, which is its investigational pan-PPAR agonist for the treatment of MASH. Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies to treat non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. While we acknowledge the potential of IVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None. Follow Insider Monkey on Google News.